

Luis L Ostrosky-Zeichner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4686312/luis-l-ostrosky-zeichner-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

128
papers

15,947
citations

47
h-index

126
g-index

137
ext. papers

18,595
ext. citations

7.3
avg, IF

6.26
L-index

#	Paper	IF	Citations
128	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial.. <i>JAMA Internal Medicine</i> , 2021 ,	11.5	13
127	Coronavirus Disease 2019-Associated Invasive Fungal Infection. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab510	1	10
126	Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. <i>Clinical Infectious Diseases</i> , 2021 , 73, e3647-e3655	11.6	22
125	Lymphatic Dissemination and Axillary Web Syndrome in Primary Cutaneous Tuberculosis Secondary to Needlestick Injury. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab160	1	1
124	Furuncular myiasis in a traveller to West Africa. <i>Journal of Travel Medicine</i> , 2021 , 28,	12.9	0
123	Investigational Agents for the Treatment of Resistant Yeasts and Molds. <i>Current Fungal Infection Reports</i> , 2021 , 15, 1-12	1.4	7
122	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases</i> , 2021 , 21, e149-e162	25.5	242
121	Reprocessing N95s with hydrogen peroxide vaporization: A robust system from collection to dispensing. <i>American Journal of Infection Control</i> , 2021 , 49, 508-511	3.8	1
120	Screening donors for COVID-19 convalescent plasma. <i>Transfusion</i> , 2021 , 61, 1047-1052	2.9	3
119	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases</i> , 2021 , 21, e375-e386	25.5	15
118	Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study. <i>Mycoses</i> , 2021 ,	5.2	2
117	Invasive Candidiasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020 , 41, 3-12	3.9	19
116	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1367-1376	11.6	607
115	Measles or Not Measles? That Is the Question!. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa311	1	
114	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020 , 222, S175-S198	7	39
113	Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2020 , 49, 77	5.4	7
112	Point-Counterpoint: Should Serum β -D-Glucan Testing Be Used for the Diagnosis of <i>Pneumocystis jirovecii</i> Pneumonia?. <i>Journal of Clinical Microbiology</i> , 2019 , 58,	9.7	6

111	Prevention and Treatment of Yeast and Endemic Fungal Infections 2019 , 179-199		
110	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3056-3062	5.1	29
109	Seroprevalence of <i>Strongyloides stercoralis</i> and Evaluation of Universal Screening in Kidney Transplant Candidates: A Single-Center Experience in Houston (2012-2017). <i>Open Forum Infectious Diseases</i> , 2019 , 6,	1	8
108	Update on the Diagnosis of Candidemia and Invasive Candidiasis. <i>Current Fungal Infection Reports</i> , 2019 , 13, 301-307	1.4	3
107	Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1981-1989	11.6	81
106	Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. <i>Mycoses</i> , 2018 , 61, 485-497	5.2	20
105	Isavuconazole for treatment of rare invasive fungal diseases. <i>Mycoses</i> , 2018 , 61, 518-533	5.2	26
104	Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1678-1686	11.6	98
103	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. <i>Mycoses</i> , 2018 , 61, 420-429	5.2	17
102	Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals. <i>Journal of Clinical Microbiology</i> , 2018 , 56,	9.7	10
101	113. Accuracy of the NHSN Central Line-Associated Bloodstream Infection (CLABSI) Definition. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S3-S3	1	2
100	369. Using Hybrid Models and Blockchain Technology as a Means to Develop a Novel Propensity Score for Candidemia and Invasive Candidiasis. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S144-S145	1	1
99	2045. Pitfalls in the Use of MALDI TOF Mass Spectrometry for the Identification of Problematic Yeast Isolates from a Historical Collection. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S596-S597	1	78
98	1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S52-S52	1	5
97	Post-exposure prophylaxis with isavuconazole after occupational exposure to. <i>Oxford Medical Case Reports</i> , 2018 , 2018, omy062	0.6	4
96	A Risk Score for Fluconazole Failure among Patients with Candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	7
95	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. <i>Intensive Care Medicine</i> , 2017 , 43, 1225-1238	14.5	90
94	Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S52-S52	1	78

93	Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis. <i>BMC Infectious Diseases</i> , 2017 , 17, 753	4	11
92	A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx200	1	28
91	Drugs in Clinical Development for Fungal Infections. <i>Drugs</i> , 2017 , 77, 1505-1518	12.1	41
90	Thinking beyond the Common Candida Species: Need for Species-Level Identification of Candida Due to the Emergence of Multidrug-Resistant Candida auris. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 3324-3327	9.7	44
89	Progressive Dispersion of Azole Resistance in <i>Aspergillus fumigatus</i> : Fatal Invasive Aspergillosis in a Patient with Acute Myeloid Leukemia Infected with an A. fumigatus Strain with a TR Y121F M172I T289A Allele. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	8
88	Invasive Fungal Infections in the Intensive Care Unit. <i>Infectious Disease Clinics of North America</i> , 2017 , 31, 475-487	6.5	27
87	The Role of In Vitro Susceptibility Testing in the Management of Candida and <i>Aspergillus</i> . <i>Journal of Infectious Diseases</i> , 2017 , 216, S452-S457	7	13
86	40 years of medical mycology at JAC. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3327-3329	5.1	
85	Clinical Characteristics and Predictors of Adverse Outcome in Adult and Pediatric Patients With Healthcare-Associated Ventriculitis and Meningitis. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw077	1	28
84	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016 , 62, 409-17	11.6	1105
83	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , 2016 , 16, 828-837	25.5	382
82	Fungal Infections. <i>Infectious Disease Clinics of North America</i> , 2016 , 30, xiii-xiv	6.5	2
81	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016 , 62, e1-50	11.6	1655
80	Epidemiology and Management of Candidiasis in Solid Organ Transplant Recipients. <i>Current Fungal Infection Reports</i> , 2016 , 10, 147-152	1.4	1
79	Fungal Diagnostics: A Practical Approach. <i>Current Clinical Microbiology Reports</i> , 2016 , 3, 103-110	3.1	
78	Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to <i>Candida parapsilosis</i> : a retrospective observational cohort study of the Mycoses Study Group (MSG-12). <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3536-3539	5.1	27
77	Antifungal Susceptibility Testing: Evolution, Indications, and Role in Clinical Practice. <i>Current Treatment Options in Infectious Diseases</i> , 2015 , 7, 155-162	1	2
76	Tigecycline : a critical safety review. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 335-42	4.1	45

75	Cefepime free minimum concentration to minimum inhibitory concentration (FC _{min} /MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 541-4	14.3	43
74	T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. <i>Clinical Infectious Diseases</i> , 2015 , 60, 892-9	11.6	305
73	MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1219-26	11.6	117
72	What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. <i>Intensive Care Medicine</i> , 2014 , 40, 808-19	14.5	75
71	Surveillance of <i>Candida</i> spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitals. <i>PLoS ONE</i> , 2014 , 9, e97325	3.7	21
70	New serological markers in medical mycology: (1,3)- β -D-glucan and <i>Aspergillus</i> galactomannan. <i>Infectio</i> , 2012 , 16, 59-63	0.7	3
69	(1,3)- β -D-glucan as a prognostic marker of treatment response in invasive candidiasis. <i>Clinical Infectious Diseases</i> , 2012 , 55, 521-6	11.6	96
68	Invasive mycoses: diagnostic challenges. <i>American Journal of Medicine</i> , 2012 , 125, S14-24	2.4	148
67	Correlation of clinical outcomes with β -glucan levels in patients with invasive candidiasis. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 2104-6	9.7	48
66	Neonatal Fungal Infections 2012 , 287-302		1
65	Early treatment of candidemia in adults: a review. <i>Medical Mycology</i> , 2011 , 49, 113-20	3.9	67
64	Clinical breakpoints for voriconazole and <i>Candida</i> spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011 , 70, 330-43	2.9	106
63	Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. <i>Mycoses</i> , 2011 , 54, 46-51	5.2	85
62	High-Dose Caspofungin is Safe for Adult Patients with Invasive Candidiasis. <i>Current Fungal Infection Reports</i> , 2011 , 5, 1-2	1.4	1
61	Clinical prediction rules for invasive candidiasis in the ICU: ready for prime time?. <i>Critical Care</i> , 2011 , 15, 189	10.8	11
60	Prospective survey of (1 \rightarrow 3)- β -D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 58-61	9.7	83
59	Multilaboratory testing of two-drug combinations of antifungals against <i>Candida albicans</i> , <i>Candida glabrata</i> , and <i>Candida parapsilosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 1543-8	5.9	29
58	An insight into the antifungal pipeline: selected new molecules and beyond. <i>Nature Reviews Drug Discovery</i> , 2010 , 9, 719-27	64.1	305

57	Invasive candidiasis in the intensive care unit. <i>Hospital Practice (1995)</i> , 2010 , 38, 82-91	2.2	1
56	Early antifungal intervention strategies in ICU patients. <i>Current Opinion in Critical Care</i> , 2010 , 16, 465-9	3.5	21
55	Activity of anidulafungin in a murine model of <i>Candida krusei</i> infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1639-41	5.9	11
54	Can fungal biomarkers be used to improve antifungal therapy in the intensive care unit?. <i>Current Fungal Infection Reports</i> , 2009 , 3, 147-151	1.4	
53	Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2009 , 48, 503-35	11.6	2247
52	Issues in the design and interpretation of antifungal drug trials in the critically ill. <i>Current Opinion in Infectious Diseases</i> , 2009 , 22, 564-7	5.4	5
51	Fungal and Parasitic Infections 2009 , 113-134		
50	Current options in antifungal pharmacotherapy. <i>Pharmacotherapy</i> , 2008 , 28, 614-45	5.8	60
49	Antifungal and Antiviral Therapy 2008 , 1089-1109		1
48	Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing <i>Candida</i> spp. by the CLSI M27-A2 standard method. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 4175-7	5.9	35
47	Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. <i>Clinical Infectious Diseases</i> , 2008 , 47, 674-83	11.6	308
46	Multilaboratory testing of antifungal combinations against a quality control isolate of <i>Candida krusei</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1500-2	5.9	24
45	Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1891-3	5.9	48
44	Neonatal Fungal Infections 2008 , 262-278		
43	Prophylaxis for <i>Candida</i> in the intensive care unit patient. <i>Current Fungal Infection Reports</i> , 2008 , 2, 69-73.4		
42	Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center. <i>Archives of Medical Research</i> , 2007 , 38, 90-3	6.6	35
41	Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2007 , 26, 271-6	5.3	277
40	Effects of serum on in vitro susceptibility testing of echinocandins. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 4214-6	5.9	60

39	Anidulafungin: a new addition to the antifungal armamentarium. <i>Therapy: Open Access in Clinical Medicine</i> , 2007 , 4, 125-132		1
38	Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. <i>Lancet, The</i> , 2007 , 369, 1519-1527	40	1092
37	Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. <i>Clinical Infectious Diseases</i> , 2007 , 45, 883-93	11.6	1030
36	Invasive Yeast Infections. <i>Infectious Disease and Therapy</i> , 2007 , 221-238		1
35	Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against <i>Candida</i> spp. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 2105-8	9.7	33
34	Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 143-7	5.9	138
33	Differences in beta-glucan levels in culture supernatants of a variety of fungi. <i>Medical Mycology</i> , 2006 , 44, 267-72	3.9	97
32	Invasive candidiasis in the intensive care unit. <i>Critical Care Medicine</i> , 2006 , 34, 857-63	1.4	179
31	Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. <i>Medical Mycology</i> , 2005 , 43, 235-43	3.9	144
30	Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2617-32	4	22
29	Cost of a ventilator-associated pneumonia in a shock trauma intensive care unit. <i>Surgical Infections</i> , 2005 , 6, 65-72	2	65
28	In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against <i>Aspergillus</i> spp. and <i>Fusarium</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 3572-4	5.9	63
27	Invasive candidiasis in immunocompromised hospitalized patients. <i>Archives of Medical Research</i> , 2005 , 36, 660-71	6.6	87
26	Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation. <i>Pharmacotherapy</i> , 2005 , 25, 426-8	5.8	18
25	Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. <i>Clinical Infectious Diseases</i> , 2005 , 40 Suppl 6, S409-13	11.6	38
24	Syscan3, a kit for detection of anti- <i>Candida</i> antibodies for diagnosis of invasive candidiasis. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 4834-5	9.7	22
23	Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. <i>Clinical Infectious Diseases</i> , 2005 , 41, 654-9	11.6	560
22	Novel approaches to antifungal prophylaxis. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 665-72	5.9	2

21	Interlaboratory comparison of results of susceptibility testing with caspofungin against <i>Candida</i> and <i>Aspergillus</i> species. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3475-82	9.7	163
20	Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 3151-3	5.9	28
19	In vitro activity of anidulafungin against selected clinically important mold isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 1912-5	5.9	67
18	Therapy of common superficial fungal infections. <i>Dermatologic Therapy</i> , 2004 , 17, 517-22	2.2	17
17	Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. <i>Clinical Infectious Diseases</i> , 2004 , 39, 199-205	11.6	536
16	Associations between antibiotic use and changes in susceptibility patterns of <i>Pseudomonas aeruginosa</i> in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. <i>International Journal of Antimicrobial Agents</i> , 2004 , 24, 346-51	14.3	20
15	Combination antifungal therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 693-715	5.9	412
14	Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1647-51	5.9	182
13	Amphotericin B: time for a new "gold standard". <i>Clinical Infectious Diseases</i> , 2003 , 37, 415-25	11.6	289
12	New approaches to the risk of <i>Candida</i> in the intensive care unit. <i>Current Opinion in Infectious Diseases</i> , 2003 , 16, 533-7	5.4	57
11	Antifungal susceptibility survey of 2,000 bloodstream <i>Candida</i> isolates in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 3149-54	5.9	438
10	Peritonitis due to <i>Aspergillus</i> and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003 , 46, 49-54	2.9	37
9	In vitro activities of investigational triazoles against <i>Fusarium</i> species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 3298-300	5.9	64
8	In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical <i>Candida</i> isolates. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 1406-12	9.7	36
7	Effect of the echinocandin caspofungin on expression of <i>Candida albicans</i> secretory aspartyl proteinases and phospholipase in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 3096-100	5.9	23
6	In vitro antifungal susceptibilities of <i>Trichosporon</i> species. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 1144-6	5.9	170
5	Deeply invasive candidiasis. <i>Infectious Disease Clinics of North America</i> , 2002 , 16, 821-35	6.5	46
4	Differential antifungal activity of isomeric forms of nystatin. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 2781-6	5.9	15

- 3 Liposuction for protease-inhibitor-associated lipodystrophy. *Lancet, The*, **1999**, 353, 1244 40 36
- 2 Neurocysticercosis and HIV infection: report of two cases and review. *World Neurosurgery*, **1996**, 45, 57-61 29
- 1 New Developments in Diagnostics and Management of Invasive Candidiasis 443-448